That's the point, NEU required positive clinical trial update and then regulatory approval as with all biotech start-up stock it's the fundamental which will drive the stock valuation. If IMU doesn't provide them then the pps will drop after the consolidation like it's already doing right now, if the market drop the MC to $100M a few months after the consolidation, will you buy more in anticipation for the release of the clinical trial updates for OASIS and Azer-Cel in Q4????
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)